Bronte Capital
Our archive holds 6 letters from Bronte Capital, behind 5 investment theses and positions in 2 companies. Every quote below is copied verbatim from the letter it came from.
Bronte Capital’s own letters pageCompanies held · 2
Every company Bronte Capital has disclosed a position in across our archive, with the letter that last mentioned it.
Theses · 5
- June 2026
Alphabet is held despite search disruption because management is highly capable, the company is aggressively pivoting into AI, and the investment case hinges on whether it can replace its legacy ad business with superintelligence-driven returns.
Read the full thesis - March 2026
Coca-Cola is a stunning consumer staples business with high returns on capital, strong cash generation, and powerful brand and distribution advantages.
Read the full thesis - November 2025
Regeneron leverages proprietary genetic and mouse-model platforms to de-risk and accelerate drug discovery, offering substantial long-term upside from its current below-market valuation.
Read the full thesis - September 2025
DSM-Firmenich is undervalued at 1.6x EV/sales with structurally high-margin perfumery and fragrance segments, strong management and minimal debt.
Read the full thesis - June 2025
Holcim is an attractive investment now due to its improved profitability in Europe and the strong potential of its newly spun-off American division, Amrize.
Read the full thesis
Letter archive · 6
Funds · 2
- Bronte Capital5
- Bronte Capital Amalthea Fund1
Get Bronte Capital’s next letter the day it lands
We track Bronte Capital alongside hundreds of other managers, read every letter, and pull out what they bought and sold. Warren AI reads the whole archive for you.
View plans→